Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $89
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on DexCom (NASDAQ:DXCM) but lowers the price target from $145 to $89.
July 26, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on DexCom but lowers the price target from $145 to $89.
The lowered price target from $145 to $89 suggests a more conservative outlook on DexCom's future performance, which could negatively impact investor sentiment in the short term despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100